{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:34:48Z","timestamp":1792809288670,"version":"4.5.0"},"reference-count":416,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100017628","name":"Ines Mandl Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017628","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Howard and Georgeanna Jones Foundation","id":[{"id":"https:\/\/ror.org\/00tpvfm85","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Selective progesterone receptor modulators (SPRMs) are a new class of compounds developed to target the progesterone receptor (PR) with a mix of agonist and antagonist properties. These compounds have been introduced for the treatment of several gynecological conditions based on the critical role of progesterone in reproduction and reproductive tissues. In patients with uterine fibroids, mifepristone and ulipristal acetate have consistently demonstrated efficacy, and vilaprisan is currently under investigation, while studies of asoprisnil and telapristone were halted for safety concerns. Mifepristone demonstrated utility for the management of endometriosis, while data are limited regarding the efficacy of asoprisnil, ulipristal acetate, telapristone, and vilaprisan for this condition. Currently, none of the SPRMs have shown therapeutic success in treating endometrial cancer. Multiple SPRMs have been assessed for efficacy in treating PR-positive recurrent breast cancer, with in vivo studies suggesting a benefit of mifepristone, and multiple in vitro models suggesting the efficacy of ulipristal acetate and telapristone. Mifepristone, ulipristal acetate, vilaprisan, and asoprisnil effectively treated heavy menstrual bleeding (HBM) in patients with uterine fibroids, but limited data exist regarding the efficacy of SPRMs for HMB outside this context. A notable class effect of SPRMs are benign, PR modulator-associated endometrial changes (PAECs) due to the actions of the compounds on the endometrium. Both mifepristone and ulipristal acetate are effective for emergency contraception, and mifepristone was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of Cushing\u2019s syndrome due to its additional antiglucocorticoid effect. Based on current evidence, SPRMs show considerable promise for treatment of several gynecologic conditions.<\/jats:p>","DOI":"10.1210\/endrev\/bnaa012","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T14:27:46Z","timestamp":1588602466000},"source":"Crossref","is-referenced-by-count":144,"title":["Selective Progesterone Receptor Modulators\u2014Mechanisms and Therapeutic Utility"],"prefix":"10.1210","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-626X","authenticated-orcid":false,"given":"Md Soriful","family":"Islam","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women\u2019s Health Research, Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-9900","authenticated-orcid":false,"given":"Sadia","family":"Afrin","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women\u2019s Health Research, Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Isabel","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women\u2019s Health Research, Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-376X","authenticated-orcid":false,"given":"James","family":"Segars","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Division of Reproductive Sciences & Women\u2019s Health Research, Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"issue":"4","key":"2021121111113407800_CIT0001","first-page":"502","article-title":"Physiological action of progesterone in target tissues","volume":"18","author":"Graham","year":"1997","journal-title":"Endocr Rev."},{"issue":"6","key":"2021121111113407800_CIT0002","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/er.2003-0030","article-title":"Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones","volume":"25","author":"Payne","year":"2004","journal-title":"Endocr Rev."},{"issue":"12","key":"2021121111113407800_CIT0003","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1194\/jlr.R016675","article-title":"Early steps in steroidogenesis: intracellular cholesterol trafficking thematic review series: genetics of human lipid diseases","volume":"52","author":"Miller","year":"2011","journal-title":"J Lipid Res."},{"key":"2021121111113407800_CIT0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric."},{"issue":"10","key":"2021121111113407800_CIT0005","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids."},{"issue":"2","key":"2021121111113407800_CIT0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0022-4731(77)90040-1","article-title":"A specific progesterone receptor of myometrial cytosol from the rhesus monkey","volume":"8","author":"Illingworth","year":"1977","journal-title":"J Steroid Biochem."},{"issue":"7","key":"2021121111113407800_CIT0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABA A receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"2021121111113407800_CIT0008","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1073\/pnas.1318163111","article-title":"Pregnancy without progesterone in horses defines a second endogenous biopotent progesterone receptor agonist, 5\u03b1-dihydroprogesterone","volume":"111","author":"Scholtz","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2021121111113407800_CIT0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0092-8674(00)80900-9","article-title":"An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway","volume":"92","author":"Kliewer","year":"1998","journal-title":"Cell."},{"issue":"4","key":"2021121111113407800_CIT0010","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.ajog.2005.01.040","article-title":"Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy?","volume":"192","author":"Mitchell","year":"2005","journal-title":"Am J Obstet Gynecol."},{"issue":"3","key":"2021121111113407800_CIT0011","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/09540261.2018.1553775","article-title":"Allopregnanolone and reproductive psychiatry: an overview","volume":"31","author":"McEvoy","year":"2019","journal-title":"Int Rev Psychiatry."},{"key":"2021121111113407800_CIT0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuroscience.2011.06.076","article-title":"Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence","volume":"191","author":"Marx","year":"2011","journal-title":"Neuroscience."},{"issue":"1","key":"2021121111113407800_CIT0013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0165-0173(01)00135-7","article-title":"Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging","volume":"37","author":"Vall\u00e9e","year":"2001","journal-title":"Brain Res Brain Res Rev."},{"issue":"3","key":"2021121111113407800_CIT0014","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.brainresrev.2005.01.006","article-title":"The importance of \u201cawareness\u201d for understanding fetal pain","volume":"49","author":"Mellor","year":"2005","journal-title":"Brain Res Rev."},{"issue":"1","key":"2021121111113407800_CIT0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2005.01.049","article-title":"Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats","volume":"512","author":"B\u00e4ckstr\u00f6m","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2021121111113407800_CIT0016","first-page":"89","article-title":"Effects of steroids on gamma-aminobutyric acid receptors expressed in Xenopus oocytes by poly(A)+ RNA from mammalian brain and retina","volume":"41","author":"Woodward","year":"1992","journal-title":"Mol Pharmacol."},{"issue":"6","key":"2021121111113407800_CIT0017","doi-asserted-by":"crossref","first-page":"599.e591","DOI":"10.1016\/j.ajog.2007.05.024","article-title":"Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins","volume":"197","author":"Attardi","year":"2007","journal-title":"Am J Obstet Gynecol."},{"issue":"6","key":"2021121111113407800_CIT0018","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1159\/000374112","article-title":"Influence of 17-hydroxyprogesterone, progesterone and sex steroids on mineralocorticoid receptor transactivation in congenital adrenal hyperplasia","volume":"83","author":"Mooij","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2021121111113407800_CIT0019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/er.2012-1043","article-title":"Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Endocr Rev."},{"issue":"3","key":"2021121111113407800_CIT0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/er.2005-0001","article-title":"Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis","volume":"26","author":"Chwalisz","year":"2005","journal-title":"Endocr Rev."},{"issue":"1","key":"2021121111113407800_CIT0021","first-page":"CD001324.","article-title":"Interventions for emergency contraception","volume":"1","author":"Shen","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2021121111113407800_CIT0022","first-page":"291","article-title":"The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene","volume":"54","author":"Giangrande","year":"1999","journal-title":"Recent Prog Horm Res"},{"issue":"12","key":"2021121111113407800_CIT0023","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1210\/mend-4-12-1833","article-title":"5\u2019-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated \u201cC\u201d-receptor and unique A-receptor messages","volume":"4","author":"Wei","year":"1990","journal-title":"Mol Endocrinol."},{"key":"2021121111113407800_CIT0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000055286","article-title":"The novel isoform of the progesterone receptor cDNA in the human testis and detection of its mRNA in the human uterine endometrium","volume":"59","author":"Hirata","year":"2000","journal-title":"Oncology."},{"issue":"3","key":"2021121111113407800_CIT0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0960-0760(02)00019-5","article-title":"The novel exon, exon T, of the human progesterone receptor gene and the genomic organization of the gene","volume":"80","author":"Hirata","year":"2002","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"4","key":"2021121111113407800_CIT0026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1507\/endocrj.49.473","article-title":"Progesterone receptor mRNA variant containing novel exon insertions between exon 4 and exon 5 in human uterine endometrium","volume":"49","author":"Yamanaka","year":"2002","journal-title":"Endocr J."},{"issue":"1","key":"2021121111113407800_CIT0027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0303-7207(02)00380-5","article-title":"Cloning and expression of a novel, truncated, progesterone receptor","volume":"200","author":"Saner","year":"2003","journal-title":"Mol Cell Endocrinol."},{"issue":"5","key":"2021121111113407800_CIT0028","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","article-title":"Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B","volume":"9","author":"Kastner","year":"1990","journal-title":"Embo J."},{"issue":"10","key":"2021121111113407800_CIT0029","first-page":"1244","article-title":"Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function","volume":"7","author":"Vegeto","year":"1993","journal-title":"Mol Endocrinol."},{"issue":"6","key":"2021121111113407800_CIT0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell."},{"issue":"41","key":"2021121111113407800_CIT0031","doi-asserted-by":"crossref","first-page":"39261","DOI":"10.1074\/jbc.R300024200","article-title":"Unfolding the action of progesterone receptors","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem."},{"issue":"10","key":"2021121111113407800_CIT0032","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/j.1460-2075.1992.tb05453.x","article-title":"Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors","volume":"11","author":"Ylikomi","year":"1992","journal-title":"Embo J."},{"issue":"2","key":"2021121111113407800_CIT0033","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.mce.2011.07.017","article-title":"Structural and functional analysis of domains of the progesterone receptor","volume":"348","author":"Hill","year":"2012","journal-title":"Mol Cell Endocrinol."},{"issue":"21","key":"2021121111113407800_CIT0034","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1101\/gad.12.21.3343","article-title":"Structure and specificity of nuclear receptor-coactivator interactions","volume":"12","author":"Darimont","year":"1998","journal-title":"Genes Dev."},{"issue":"8","key":"2021121111113407800_CIT0035","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/mend.11.8.9963","article-title":"Hinge and amino-terminal sequences contribute to solution dimerization of human progesterone receptor","volume":"11","author":"Tetel","year":"1997","journal-title":"Mol Endocrinol."},{"issue":"9","key":"2021121111113407800_CIT0036","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1128\/MCB.20.9.3102-3115.2000","article-title":"The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding","volume":"20","author":"Giangrande","year":"2000","journal-title":"Mol Cell Biol."},{"issue":"7","key":"2021121111113407800_CIT0037","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/mend.14.7.0489","article-title":"Molecular chaperone interactions with steroid receptors: an update","volume":"14","author":"Cheung","year":"2000","journal-title":"Mol Endocrinol."},{"issue":"1","key":"2021121111113407800_CIT0038","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mce.2011.09.016","article-title":"Progesterone receptors, their isoforms and progesterone regulated transcription","volume":"357","author":"Jacobsen","year":"2012","journal-title":"Mol Cell Endocrinol."},{"issue":"10","key":"2021121111113407800_CIT0039","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrendo.2012.100","article-title":"Nuclear receptor coregulators: modulators of pathology and therapeutic targets","volume":"8","author":"Lonard","year":"2012","journal-title":"Nat Rev Endocrinol."},{"issue":"10","key":"2021121111113407800_CIT0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0039-128X(03)00129-6","article-title":"Progesterone receptor transcription and non-transcription signaling mechanisms","volume":"68","author":"Leonhardt","year":"2003","journal-title":"Steroids."},{"issue":"12","key":"2021121111113407800_CIT0041","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1073\/pnas.93.12.6169","article-title":"Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells","volume":"93","author":"Bamberger","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"2021121111113407800_CIT0042","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/me.2007-0437","article-title":"Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors","volume":"22","author":"Faivre","year":"2008","journal-title":"Mol Endocrinol."},{"issue":"10","key":"2021121111113407800_CIT0043","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1158\/0008-5472.CAN-10-3074","article-title":"Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer","volume":"71","author":"Cerliani","year":"2011","journal-title":"Cancer Res."},{"issue":"11","key":"2021121111113407800_CIT0044","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1074\/jbc.271.11.6217","article-title":"Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor","volume":"271","author":"Kalkhoven","year":"1996","journal-title":"J Biol Chem."},{"issue":"11","key":"2021121111113407800_CIT0045","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1074\/jbc.M009805200","article-title":"Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites","volume":"276","author":"Knotts","year":"2001","journal-title":"J Biol Chem."},{"issue":"3","key":"2021121111113407800_CIT0046","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1073\/pnas.97.3.1032","article-title":"Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome","volume":"97","author":"Lange","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"37","key":"2021121111113407800_CIT0047","doi-asserted-by":"crossref","first-page":"33950","DOI":"10.1074\/jbc.M204573200","article-title":"The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression","volume":"277","author":"Abdel-Hafiz","year":"2002","journal-title":"J Biol Chem."},{"issue":"1","key":"2021121111113407800_CIT0048","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrm1009","article-title":"Nongenomic actions of steroid hormones","volume":"4","author":"L\u00f6sel","year":"2003","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"9","key":"2021121111113407800_CIT0049","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tem.2017.05.006","article-title":"Progesterone-mediated non-classical signaling","volume":"28","author":"Garg","year":"2017","journal-title":"Trends Endocrinol Metab."},{"issue":"2","key":"2021121111113407800_CIT0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1097-2765(01)00304-5","article-title":"Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases","volume":"8","author":"Boonyaratanakornkit","year":"2001","journal-title":"Mol Cell."},{"issue":"7","key":"2021121111113407800_CIT0051","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/emboj\/17.7.2008","article-title":"Activation of the Src\/p21ras\/Erk pathway by progesterone receptor via cross-talk with estrogen receptor","volume":"17","author":"Migliaccio","year":"1998","journal-title":"Embo J."},{"issue":"5","key":"2021121111113407800_CIT0052","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1073\/pnas.0336132100","article-title":"Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2021121111113407800_CIT0053","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1073\/pnas.0436133100","article-title":"Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"2021121111113407800_CIT0054","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.steroids.2008.05.003","article-title":"Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors","volume":"73","author":"Smith","year":"2008","journal-title":"Steroids."},{"issue":"3","key":"2021121111113407800_CIT0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12672-012-0106-x","article-title":"Membrane progesterone receptors (mPRs) mediate progestin induced antimorbidity in breast cancer cells and are expressed in human breast tumors","volume":"3","author":"Dressing","year":"2012","journal-title":"Horm Cancer."},{"key":"2021121111113407800_CIT0056","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/glia.20523","article-title":"Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells","volume":"55","author":"Swiatek-De Lange","year":"2007","journal-title":"Glia"},{"issue":"2","key":"2021121111113407800_CIT0057","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1582-4934.2011.01305.x","article-title":"Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase","volume":"16","author":"Zheng","year":"2012","journal-title":"J Cell Mol Med."},{"issue":"3","key":"2021121111113407800_CIT0058","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1432-1033.1996.0726u.x","article-title":"Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes","volume":"239","author":"Meyer","year":"1996","journal-title":"Eur J Biochem."},{"issue":"7","key":"2021121111113407800_CIT0059","first-page":"907","article-title":"Cloning and tissue expression of two putative steroid membrane receptors","volume":"379","author":"Gerdes","year":"1998","journal-title":"Biol Chem."},{"issue":"1","key":"2021121111113407800_CIT0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bbrc.1996.1761","article-title":"Full-length cDNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells","volume":"229","author":"Falkenstein","year":"1996","journal-title":"Biochem Biophys Res Commun."},{"issue":"4","key":"2021121111113407800_CIT0061","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.repbio.2013.09.001","article-title":"The putative roles of nuclear and membrane-bound progesterone receptors in the female reproductive tract","volume":"13","author":"Kowalik","year":"2013","journal-title":"Reprod Biol."},{"issue":"1","key":"2021121111113407800_CIT0062","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1095\/biolreprod.105.049924","article-title":"Multiplicity of progesterone\u2019s actions and receptors in the mammalian ovary","volume":"75","author":"Peluso","year":"2006","journal-title":"Biol Reprod."},{"issue":"1","key":"2021121111113407800_CIT0063","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2007.02.002","article-title":"Progesterone receptor membrane component 1: an integrative review","volume":"105","author":"Cahill","year":"2007","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"11","key":"2021121111113407800_CIT0064","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jne.12060","article-title":"Nonclassical progesterone signalling molecules in the nervous system","volume":"25","author":"Petersen","year":"2013","journal-title":"J Neuroendocrinol."},{"key":"2021121111113407800_CIT0065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fnins.2013.00168","article-title":"PGRMC1 and PGRMC2 in uterine physiology and disease","volume":"7","author":"Pru","year":"2013","journal-title":"Front Neurosci."},{"issue":"2","key":"2021121111113407800_CIT0066","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2006.12.009","article-title":"Dap1\/PGRMC1 binds and regulates cytochrome P450 enzymes","volume":"5","author":"Hughes","year":"2007","journal-title":"Cell Metab."},{"issue":"6","key":"2021121111113407800_CIT0067","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.steroids.2012.12.002","article-title":"PGRMC2, a yet uncharacterized protein with potential as tumor suppressor, migration inhibitor, and regulator of cytochrome P450 enzyme activity","volume":"78","author":"Wendler","year":"2013","journal-title":"Steroids."},{"issue":"3","key":"2021121111113407800_CIT0068","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/aji.12473","article-title":"Progesterone-Regulated Endometrial Factors Controlling Implantation","volume":"75","author":"Bhurke","year":"2016","journal-title":"Am J Reprod Immunol."},{"issue":"1","key":"2021121111113407800_CIT0069","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jcem-67-1-80","article-title":"Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating","volume":"67","author":"Garcia","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121111113407800_CIT0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jcem-67-2-334","article-title":"Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle","volume":"67","author":"Lessey","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021121111113407800_CIT0071","first-page":"2963","article-title":"Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle","volume":"84","author":"Mote","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121111113407800_CIT0072","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/humrep\/15.suppl_3.48","article-title":"Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma","volume":"15","author":"Mote","year":"2000","journal-title":"Hum Reprod."},{"issue":"1","key":"2021121111113407800_CIT0073","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mce.2008.02.012","article-title":"Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and human","volume":"287","author":"Zhang","year":"2008","journal-title":"Mol Cell Endocrinol."},{"issue":"6","key":"2021121111113407800_CIT0074","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/molehr\/gas006","article-title":"Alterations in progesterone receptor membrane component 2 (PGRMC2) in the endometrium of macaques afflicted with advanced endometriosis","volume":"18","author":"Keator","year":"2012","journal-title":"Mol Hum Reprod."},{"issue":"2","key":"2021121111113407800_CIT0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/1933719113492208","article-title":"Expression patterns of progesterone receptor membrane components 1 and 2 in endometria from women with and without endometriosis","volume":"21","author":"Bunch","year":"2014","journal-title":"Reprod Sci."},{"issue":"1","key":"2021121111113407800_CIT0076","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/REP-09-0260","article-title":"Mechanical stretch regulates hypertrophic phenotype of the myometrium during pregnancy","volume":"139","author":"Shynlova","year":"2010","journal-title":"Reproduction."},{"issue":"5","key":"2021121111113407800_CIT0077","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2007-0077","article-title":"Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A","volume":"92","author":"Merlino","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121111113407800_CIT0078","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1038\/ncomms11565","article-title":"Molecular evidence of functional progesterone withdrawal in human myometrium","volume":"7","author":"Nadeem","year":"2016","journal-title":"Nat Commun."},{"issue":"17","key":"2021121111113407800_CIT0079","doi-asserted-by":"crossref","first-page":"9744","DOI":"10.1073\/pnas.1732707100","article-title":"Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform","volume":"100","author":"Mulac-Jericevic","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5485","key":"2021121111113407800_CIT0080","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1126\/science.289.5485.1751","article-title":"Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform","volume":"289","author":"Mulac-Jericevic","year":"2000","journal-title":"Science."},{"issue":"7","key":"2021121111113407800_CIT0081","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/me.2005-0243","article-title":"Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term","volume":"20","author":"Karteris","year":"2006","journal-title":"Mol Endocrinol."},{"key":"2021121111113407800_CIT0082","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.theriogenology.2019.08.028","article-title":"Expression of membrane progestin receptors (mPRs) \u03b1, \u03b2 and \u03b3 in the bovine uterus during the oestrous cycle and pregnancy","volume":"140","author":"Kowalik","year":"2019","journal-title":"Theriogenology."},{"issue":"12","key":"2021121111113407800_CIT0083","doi-asserted-by":"crossref","first-page":"a003178","DOI":"10.1101\/cshperspect.a003178","article-title":"Hormone action in the mammary gland","volume":"2","author":"Brisken","year":"2010","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"5","key":"2021121111113407800_CIT0084","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1210\/en.2006-1721","article-title":"Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland","volume":"148","author":"Aupperlee","year":"2007","journal-title":"Endocrinology."},{"issue":"18","key":"2021121111113407800_CIT0085","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1101\/gad.9.18.2266","article-title":"Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities","volume":"9","author":"Lydon","year":"1995","journal-title":"Genes Dev."},{"issue":"2","key":"2021121111113407800_CIT0086","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1073\/pnas.95.2.696","article-title":"Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands","volume":"95","author":"Shyamala","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"2021121111113407800_CIT0087","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/en.2005-0346","article-title":"Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development","volume":"146","author":"Aupperlee","year":"2005","journal-title":"Endocrinology."},{"issue":"6","key":"2021121111113407800_CIT0088","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","article-title":"Variation in the incidence of uterine leiomyoma among premenopausal women by age and race","volume":"90","author":"Marshall","year":"1997","journal-title":"Obstet Gynecol."},{"issue":"6","key":"2021121111113407800_CIT0089","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1933719118812720","article-title":"1, 25 Dihydroxyvitamin D3 enhances the antifibroid effects of ulipristal acetate in human uterine fibroids","volume":"26","author":"Ali","year":"2018","journal-title":"Reprod Sci"},{"issue":"3","key":"2021121111113407800_CIT0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09513590.2017.1391774","article-title":"25-Hydroxy vitamin D levels in premenopausal Turkish women with uterine leiomyoma","volume":"34","author":"Oskovi Kaplan","year":"2018","journal-title":"Gynecol Endocrinol."},{"issue":"52","key":"2021121111113407800_CIT0091","doi-asserted-by":"crossref","first-page":"e5698","DOI":"10.1097\/MD.0000000000005698","article-title":"Hypovitaminosis D and \u201csmall burden\u201d uterine fibroids: opportunity for a vitamin D supplementation","volume":"95","author":"Ciavattini","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"2021121111113407800_CIT0092","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ajcn\/76.1.187","article-title":"Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"76","author":"Nesby-O\u2019Dell","year":"2002","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2021121111113407800_CIT0093","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ajcp\/94.4.435","article-title":"The frequency of uterine leiomyomas","volume":"94","author":"Cramer","year":"1990","journal-title":"Am J Clin Pathol."},{"issue":"4","key":"2021121111113407800_CIT0094","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0015-0282(16)45789-4","article-title":"Uterine leiomyomata: etiology, symptomatology, and management","volume":"36","author":"Buttram","year":"1981","journal-title":"Fertil Steril."},{"issue":"12","key":"2021121111113407800_CIT0095","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1093\/humrep\/der293","article-title":"The prevalence and impact of fibroids and their treatment on the outcome of pregnancy in women with recurrent miscarriage","volume":"26","author":"Saravelos","year":"2011","journal-title":"Hum Reprod."},{"issue":"4","key":"2021121111113407800_CIT0096","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.fertnstert.2008.01.051","article-title":"Fibroids and infertility: an updated systematic review of the evidence","volume":"91","author":"Pritts","year":"2009","journal-title":"Fertil Steril."},{"issue":"6","key":"2021121111113407800_CIT0097","first-page":"211.e211","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"2021121111113407800_CIT0098","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0002-9378(15)30365-3","article-title":"Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase","volume":"107","author":"Townsend","year":"1970","journal-title":"Am J Obstet Gynecol."},{"issue":"3692","key":"2021121111113407800_CIT0099","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1126\/science.150.3692.67","article-title":"Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas","volume":"150","author":"Linder","year":"1965","journal-title":"Science."},{"issue":"1","key":"2021121111113407800_CIT0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.2870110102","article-title":"Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata","volume":"11","author":"Mashal","year":"1994","journal-title":"Genes Chromosomes Cancer."},{"issue":"6","key":"2021121111113407800_CIT0101","first-page":"1379","article-title":"X-chromosomal inactivation analysis of uterine leiomyomas reveals a common clonal origin of different tumor nodules in some multiple leiomyomas","volume":"31","author":"Cai","year":"2007","journal-title":"Int J Oncol."},{"issue":"50","key":"2021121111113407800_CIT0102","doi-asserted-by":"crossref","first-page":"19887","DOI":"10.1073\/pnas.0808188105","article-title":"Growth of uterine leiomyomata among premenopausal black and white women","volume":"105","author":"Peddada","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2021121111113407800_CIT0103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121111113407800_CIT0104","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/oxfordjournals.humrep.a138762","article-title":"Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin \u2018add-back\u2019 for 2 years","volume":"9","author":"Friedman","year":"1994","journal-title":"Hum Reprod."},{"issue":"4","key":"2021121111113407800_CIT0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01606522","article-title":"Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy","volume":"419","author":"Kawaguchi","year":"1991","journal-title":"Virchows Arch A Pathol Anat Histopathol."},{"issue":"3","key":"2021121111113407800_CIT0106","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0002-9378(89)80046-8","article-title":"Mitotic activity in uterine leiomyomas during the menstrual cycle","volume":"160","author":"Kawaguchi","year":"1989","journal-title":"Am J Obstet Gynecol."},{"issue":"1","key":"2021121111113407800_CIT0107","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/humupd\/dmx032","article-title":"Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics","volume":"24","author":"Islam","year":"2018","journal-title":"Hum Reprod Update."},{"issue":"6053","key":"2021121111113407800_CIT0108","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"M\u00e4kinen","year":"2011","journal-title":"Science."},{"issue":"24","key":"2021121111113407800_CIT0109","first-page":"4288","article-title":"Biallelic mutations in human NHLRC2 enhance myofibroblast differentiation in FINCA disease","volume":"27","author":"Paakkola","year":"2018","journal-title":"Hum Mol Genet."},{"issue":"1","key":"2021121111113407800_CIT0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.fertnstert.2013.03.007","article-title":"Complex networks of multiple factors in the pathogenesis of uterine leiomyoma","volume":"100","author":"Islam","year":"2013","journal-title":"Fertil Steril."},{"issue":"1","key":"2021121111113407800_CIT0111","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9378(93)90135-6","article-title":"Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas","volume":"169","author":"Brandon","year":"1993","journal-title":"Am J Obstet Gynecol."},{"issue":"1","key":"2021121111113407800_CIT0112","first-page":"293","article-title":"Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone","volume":"82","author":"Matsuo","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021121111113407800_CIT0113","first-page":"2192","article-title":"Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma","volume":"83","author":"Shimomura","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021121111113407800_CIT0114","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(00)00418-0","article-title":"Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation","volume":"73","author":"Arici","year":"2000","journal-title":"Fertil Steril."},{"issue":"5","key":"2021121111113407800_CIT0115","first-page":"2275","article-title":"Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone","volume":"86","author":"Kurachi","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021121111113407800_CIT0116","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/jc.2008-2093","article-title":"Progestins activate the AKT pathway in leiomyoma cells and promote survival","volume":"94","author":"Hoekstra","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"6281","key":"2021121111113407800_CIT0117","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/346281a0","article-title":"Negative regulation of transforming growth factor-beta by the proteoglycan decorin","volume":"346","author":"Yamaguchi","year":"1990","journal-title":"Nature."},{"issue":"5","key":"2021121111113407800_CIT0118","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.fertnstert.2009.01.081","article-title":"Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3","volume":"93","author":"Joseph","year":"2010","journal-title":"Fertil Steril."},{"issue":"3","key":"2021121111113407800_CIT0119","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1933719115607994","article-title":"Proteoglycans in leiomyoma and normal myometrium: abundance, steroid hormone control, and implications for pathophysiology","volume":"23","author":"Barker","year":"2016","journal-title":"Reprod Sci."},{"key":"2021121111113407800_CIT0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omto.2018.12.011","article-title":"Systematic review of miR-29 in cancer","volume":"12","author":"Kwon","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"3","key":"2021121111113407800_CIT0121","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1210\/en.2013-1763","article-title":"Down-regulation of miR-29b is essential for pathogenesis of uterine leiomyoma","volume":"155","author":"Qiang","year":"2014","journal-title":"Endocrinology."},{"issue":"11","key":"2021121111113407800_CIT0122","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1210\/jc.2009-1286","article-title":"Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells","volume":"94","author":"Luo","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021121111113407800_CIT0123","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet Gynecol."},{"issue":"1","key":"2021121111113407800_CIT0124","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol."},{"issue":"8","key":"2021121111113407800_CIT0125","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod."},{"key":"2021121111113407800_CIT0126","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJWH.S42770","article-title":"Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial","volume":"5","author":"Esteve","year":"2013","journal-title":"Int J Womens Health."},{"issue":"4","key":"2021121111113407800_CIT0127","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-09-2612","article-title":"Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells","volume":"70","author":"Yin","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"2021121111113407800_CIT0128","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/er.2018-00242","article-title":"Endometriosis","volume":"40","author":"Bulun","year":"2019","journal-title":"Endocr Rev."},{"issue":"4","key":"2021121111113407800_CIT0129","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9378(15)30003-X","article-title":"Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity","volume":"14","author":"Sampson","year":"1927","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2021121111113407800_CIT0130","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/cam4.1445","article-title":"Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses","volume":"7","author":"Painter","year":"2018","journal-title":"Cancer Med."},{"key":"2021121111113407800_CIT0131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpobgyn.2018.06.001","article-title":"Risk for and consequences of endometriosis: a critical epidemiologic review","volume":"51","author":"Shafrir","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"issue":"1","key":"2021121111113407800_CIT0132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2017.05.031","article-title":"Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why","volume":"108","author":"Lessey","year":"2017","journal-title":"Fertil Steril."},{"issue":"02","key":"2021121111113407800_CIT0133","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-2003-41326","volume":"21","author":"Spaczynski","year":"2003","journal-title":"Semin Reprod Med."},{"key":"2021121111113407800_CIT0134","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/1933719116654991","article-title":"Research priorities for endometriosis","volume":"24","author":"Rogers","year":"2017","journal-title":"Reprod Sci"},{"issue":"6","key":"2021121111113407800_CIT0135","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1210\/endo.143.6.8885","article-title":"Global gene profiling in human endometrium during the window of implantation","volume":"143","author":"Kao","year":"2002","journal-title":"Endocrinology."},{"issue":"4","key":"2021121111113407800_CIT0136","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/humupd\/dmz005","article-title":"Endometriosis and nuclear receptors","volume":"25","author":"Yilmaz","year":"2019","journal-title":"Hum Reprod Update."},{"issue":"10","key":"2021121111113407800_CIT0137","doi-asserted-by":"crossref","first-page":"e0165347","DOI":"10.1371\/journal.pone.0165347","article-title":"Progesterone alleviates endometriosis via inhibition of uterine cell proliferation, inflammation and angiogenesis in an immunocompetent mouse model","volume":"11","author":"Li","year":"2016","journal-title":"Plos One."},{"issue":"8","key":"2021121111113407800_CIT0138","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tem.2018.05.006","article-title":"Progesterone resistance in endometriosis: an acquired property?","volume":"29","author":"McKinnon","year":"2018","journal-title":"Trends Endocrinol Metab."},{"issue":"11","key":"2021121111113407800_CIT0139","doi-asserted-by":"crossref","first-page":"E2188","DOI":"10.1210\/jc.2014-1913","article-title":"Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions","volume":"99","author":"Huhtinen","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021121111113407800_CIT0140","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1210\/jc.2012-1154","article-title":"Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels","volume":"97","author":"Huhtinen","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021121111113407800_CIT0141","first-page":"2897","article-title":"Progesterone receptor isoform A but not B is expressed in endometriosis","volume":"85","author":"Attia","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021121111113407800_CIT0142","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1210\/en.2006-1692","article-title":"Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis","volume":"148","author":"Burney","year":"2007","journal-title":"Endocrinology."},{"issue":"7","key":"2021121111113407800_CIT0143","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1210\/en.2003-0043","article-title":"Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility","volume":"144","author":"Kao","year":"2003","journal-title":"Endocrinology."},{"issue":"12","key":"2021121111113407800_CIT0144","first-page":"2093","article-title":"Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2","volume":"15","author":"Yang","year":"2001","journal-title":"Mol Endocrinol."},{"issue":"5","key":"2021121111113407800_CIT0145","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2007-1536","article-title":"Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1\/SP3 for estradiol metabolism","volume":"93","author":"Cheng","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021121111113407800_CIT0146","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1172\/JCI117569","article-title":"17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium","volume":"94","author":"Casey","year":"1994","journal-title":"J Clin Invest."},{"issue":"4","key":"2021121111113407800_CIT0147","doi-asserted-by":"crossref","first-page":"391.e391","DOI":"10.1016\/j.ajog.2006.12.014","article-title":"Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17\u03b2-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism","volume":"196","author":"Cheng","year":"2007","journal-title":"Am J Obstet Gynecol."},{"issue":"12","key":"2021121111113407800_CIT0148","first-page":"4474","article-title":"Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol","volume":"83","author":"Zeitoun","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121111113407800_CIT0149","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.fertnstert.2004.01.048","article-title":"Intact progesterone receptors are essential to counteract the proliferative effect of estradiol in a genetically engineered mouse model of endometriosis","volume":"82","author":"Fang","year":"2004","journal-title":"Fertil Steril."},{"issue":"17","key":"2021121111113407800_CIT0150","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ejca.2014.09.003","article-title":"Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions","volume":"50","author":"Tangen","year":"2014","journal-title":"Eur J Cancer."},{"issue":"5","key":"2021121111113407800_CIT0151","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrendo.2013.255","article-title":"Endometriosis: pathogenesis and treatment","volume":"10","author":"Vercellini","year":"2014","journal-title":"Nat Rev Endocrinol."},{"issue":"5","key":"2021121111113407800_CIT0152","doi-asserted-by":"crossref","first-page":"e97311","DOI":"10.1371\/journal.pone.0097311","article-title":"CDC2 mediates progestin initiated endometrial stromal cell proliferation: a PR signaling to gene expression independently of its binding to chromatin","volume":"9","author":"Vallejo","year":"2014","journal-title":"Plos One."},{"issue":"12","key":"2021121111113407800_CIT0153","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1210\/jc.2018-01227","article-title":"Progesterone receptor status predicts response to progestin therapy in endometriosis","volume":"103","author":"Flores","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"9484","key":"2021121111113407800_CIT0154","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet."},{"issue":"1","key":"2021121111113407800_CIT0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"6","key":"2021121111113407800_CIT0156","first-page":"699","article-title":"Endometrial carcinoma in women 40 years of age or younger","volume":"57","author":"Crissman","year":"1981","journal-title":"Obstet Gynecol."},{"issue":"11","key":"2021121111113407800_CIT0157","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.2174\/13816128113199990532","article-title":"Epigenetic modification restores functional PR expression in endometrial cancer cells","volume":"20","author":"Yang","year":"2014","journal-title":"Curr Pharm Des."},{"issue":"6","key":"2021121111113407800_CIT0158","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccr.2004.05.029","article-title":"Focus on endometrial and cervical cancer","volume":"5","author":"Ellenson","year":"2004","journal-title":"Cancer Cell."},{"issue":"7447","key":"2021121111113407800_CIT0159","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"9","key":"2021121111113407800_CIT0160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(15)00212-0","article-title":"Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies","volume":"16","author":"Allen","year":"2015","journal-title":"Lancet Oncol"},{"issue":"37","key":"2021121111113407800_CIT0161","doi-asserted-by":"crossref","first-page":"e8034","DOI":"10.1097\/MD.0000000000008034","article-title":"Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review","volume":"96","author":"Wei","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"9470","key":"2021121111113407800_CIT0162","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet."},{"key":"2021121111113407800_CIT0163","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.maturitas.2016.05.013","article-title":"Hormone replacement therapy and the risk of endometrial cancer: a systematic review","volume":"91","author":"Sj\u00f6gren","year":"2016","journal-title":"Maturitas"},{"issue":"2","key":"2021121111113407800_CIT0164","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2","article-title":"Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature","volume":"79","author":"Kim","year":"1997","journal-title":"Cancer."},{"issue":"2","key":"2021121111113407800_CIT0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol."},{"issue":"9","key":"2021121111113407800_CIT0166","first-page":"1860","article-title":"Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action","volume":"58","author":"Kumar","year":"1998","journal-title":"Cancer Res."},{"issue":"3","key":"2021121111113407800_CIT0167","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","author":"Jongen","year":"2009","journal-title":"Gynecol Oncol."},{"issue":"4","key":"2021121111113407800_CIT0168","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000217942","article-title":"Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors","volume":"16","author":"Fujimoto","year":"1995","journal-title":"Tumour Biol."},{"issue":"11","key":"2021121111113407800_CIT0169","first-page":"4576","article-title":"Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium","volume":"61","author":"Arnett-Mansfield","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"2021121111113407800_CIT0170","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1210\/jc.2003-031111","article-title":"Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium","volume":"89","author":"Arnett-Mansfield","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021121111113407800_CIT0171","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1210\/en.2007-0756","article-title":"The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma","volume":"149","author":"Ward","year":"2008","journal-title":"Endocrinology."},{"issue":"3","key":"2021121111113407800_CIT0172","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1078-0432.CCR-10-1287","article-title":"Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth","volume":"17","author":"Kyo","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021121111113407800_CIT0173","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canlet.2013.04.010","article-title":"The PRB-dependent FOXO1\/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth","volume":"336","author":"Nakamura","year":"2013","journal-title":"Cancer Lett."},{"issue":"10","key":"2021121111113407800_CIT0174","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1940-6207.CAPR-14-0054","article-title":"Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGF\u03b2 pathway","volume":"7","author":"Bokhari","year":"2014","journal-title":"Cancer Prev Res (Phila)."},{"issue":"3","key":"2021121111113407800_CIT0175","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama."},{"issue":"2","key":"2021121111113407800_CIT0176","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014820500738","article-title":"Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis","volume":"72","author":"Mote","year":"2002","journal-title":"Breast Cancer Res Treat."},{"issue":"21","key":"2021121111113407800_CIT0177","first-page":"5063","article-title":"Characterization of progesterone receptor A and B expression in human breast cancer","volume":"55","author":"Graham","year":"1995","journal-title":"Cancer Res."},{"issue":"8","key":"2021121111113407800_CIT0178","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-03-0141","article-title":"Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates","volume":"10","author":"Hopp","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021121111113407800_CIT0179","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10549-015-3397-0","article-title":"Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial","volume":"151","author":"Mote","year":"2015","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"2021121111113407800_CIT0180","doi-asserted-by":"crossref","first-page":"djw317","DOI":"10.1093\/jnci\/djw317","article-title":"Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness","volume":"109","author":"Rojas","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2021121111113407800_CIT0181","first-page":"5032","article-title":"Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes","volume":"11","author":"Musgrove","year":"1991","journal-title":"Mol Cell Biol."},{"issue":"11","key":"2021121111113407800_CIT0182","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/mend.11.11.0006","article-title":"Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1)","volume":"11","author":"Groshong","year":"1997","journal-title":"Mol Endocrinol."},{"issue":"1","key":"2021121111113407800_CIT0183","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01833357","article-title":"Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF","volume":"20","author":"Gill","year":"1991","journal-title":"Breast Cancer Res Treat."},{"issue":"17","key":"2021121111113407800_CIT0184","doi-asserted-by":"crossref","first-page":"10696","DOI":"10.1074\/jbc.273.17.10696","article-title":"Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP\/p300","volume":"273","author":"Owen","year":"1998","journal-title":"J Biol Chem."},{"issue":"7","key":"2021121111113407800_CIT0185","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1128\/MCB.20.7.2581-2591.2000","article-title":"Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells","volume":"20","author":"Swarbrick","year":"2000","journal-title":"Mol Cell Biol."},{"issue":"20","key":"2021121111113407800_CIT0186","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/MCB.00326-06","article-title":"TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone","volume":"26","author":"Gizard","year":"2006","journal-title":"Mol Cell Biol."},{"issue":"50","key":"2021121111113407800_CIT0187","doi-asserted-by":"crossref","first-page":"43091","DOI":"10.1074\/jbc.M111.295865","article-title":"Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1\/DUSP1)","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol Chem."},{"issue":"8","key":"2021121111113407800_CIT0188","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/djt043","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in the Women\u2019s Health Initiative Observational Study","volume":"105","author":"Chlebowski","year":"2013","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"2021121111113407800_CIT0189","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jsbmb.2005.09.008","article-title":"Progestin inhibition of cell death in human breast cancer cell lines","volume":"98","author":"Moore","year":"2006","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"11","key":"2021121111113407800_CIT0190","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1210\/en.2004-1535","article-title":"Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase\/Akt\/nuclear factor-kappaB cascade in human breast cancer cells","volume":"146","author":"Saitoh","year":"2005","journal-title":"Endocrinology."},{"issue":"2","key":"2021121111113407800_CIT0191","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-005-7726-6","article-title":"Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75","volume":"94","author":"Carvajal","year":"2005","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"2021121111113407800_CIT0192","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1128\/MCB.01539-06","article-title":"Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1\/2 mitogen-activated protein kinase in breast cancer cells","volume":"27","author":"Faivre","year":"2007","journal-title":"Mol Cell Biol."},{"key":"2021121111113407800_CIT0193","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1289\/ehp.00108s5785","article-title":"Regulation of vascular endothelial growth factor expression by estrogens and progestins","volume":"108","author":"Hyder","year":"2000","journal-title":"Environ Health Perspect."},{"issue":"7299","key":"2021121111113407800_CIT0194","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nature09091","article-title":"Progesterone induces adult mammary stem cell expansion","volume":"465","author":"Joshi","year":"2010","journal-title":"Nature."},{"issue":"1","key":"2021121111113407800_CIT0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1078-0432.193.11.1","article-title":"ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021121111113407800_CIT0196","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbrc.2012.11.009","article-title":"Upregulation of ATBF1 by progesterone-PR signaling and its functional implication in mammary epithelial cells","volume":"430","author":"Li","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"issue":"3","key":"2021121111113407800_CIT0197","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/med.20083","article-title":"The evolution of progesterone receptor ligands","volume":"27","author":"Madauss","year":"2007","journal-title":"Med Res Rev."},{"issue":"3","key":"2021121111113407800_CIT0198","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/biolre\/iox094","article-title":"Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids","volume":"97","author":"Ali","year":"2017","journal-title":"Biol Reprod."},{"issue":"5","key":"2021121111113407800_CIT0199","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil Steril."},{"issue":"27","key":"2021121111113407800_CIT0200","doi-asserted-by":"crossref","first-page":"19513","DOI":"10.1016\/S0021-9258(18)41805-4","article-title":"Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation","volume":"267","author":"Allan","year":"1992","journal-title":"J Biol Chem."},{"issue":"4","key":"2021121111113407800_CIT0201","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(92)90234-4","article-title":"The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor","volume":"69","author":"Vegeto","year":"1992","journal-title":"Cell."},{"issue":"6","key":"2021121111113407800_CIT0202","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/jcem-71-6-1474","article-title":"Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects","volume":"71","author":"Laue","year":"1990","journal-title":"J Clin Endocrinol Metab."},{"issue":"24","key":"2021121111113407800_CIT0203","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/jnci\/92.24.1970","article-title":"Effect of mifepristone approval on research remains to be seen","volume":"92","author":"Vastag","year":"2000","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"2021121111113407800_CIT0204","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-4731(87)90083-5","article-title":"Plasma concentrations and receptor binding of RU 486 and its metabolites in humans","volume":"26","author":"Oskari","year":"1987","journal-title":"J Steroid Biochem"},{"issue":"3","key":"2021121111113407800_CIT0205","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2003.12.004","article-title":"In vitro antiprogestational\/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone","volume":"88","author":"Attardi","year":"2004","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"1","key":"2021121111113407800_CIT0206","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0303-7207(01)00743-2","article-title":"CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914","volume":"188","author":"Attardi","year":"2002","journal-title":"Mol Cell Endocrinol."},{"issue":"6","key":"2021121111113407800_CIT0207","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0010-7824(03)00077-5","article-title":"The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action","volume":"68","author":"Heikinheimo","year":"2003","journal-title":"Contraception."},{"issue":"5","key":"2021121111113407800_CIT0208","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/med.21311","article-title":"The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis","volume":"34","author":"Chen","year":"2014","journal-title":"Med Res Rev."},{"key":"2021121111113407800_CIT0209","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.bi.63.070194.002315","article-title":"Molecular mechanisms of action of steroid\/thyroid receptor superfamily members","volume":"63","author":"Tsai","year":"1994","journal-title":"Annu Rev Biochem."},{"issue":"2","key":"2021121111113407800_CIT0210","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00003081-199606000-00017","article-title":"Mifepristone: clinical pharmacology","volume":"39","author":"Robbins","year":"1996","journal-title":"Clin Obstet Gynecol."},{"issue":"14","key":"2021121111113407800_CIT0211","first-page":"3868","article-title":"New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP","volume":"54","author":"Sartorius","year":"1994","journal-title":"Cancer Res."},{"issue":"1","key":"2021121111113407800_CIT0212","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/07853899309147861","article-title":"Dose-response relationships of RU 486","volume":"25","author":"Heikinheimo","year":"1993","journal-title":"Ann Med."},{"issue":"1","key":"2021121111113407800_CIT0213","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0010-7824(96)00116-3","article-title":"Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study","volume":"54","author":"F\u00f6ldesi","year":"1996","journal-title":"Contraception."},{"issue":"4","key":"2021121111113407800_CIT0214","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0010-7824(96)00193-X","article-title":"Pharmacokinetics of mifepristone after low oral doses","volume":"54","author":"Kekkonen","year":"1996","journal-title":"Contraception."},{"issue":"6","key":"2021121111113407800_CIT0215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0010-7824(03)00181-1","article-title":"Pharmacokinetics of 10 mg of mifepristone","volume":"68","author":"Leminen","year":"2003","journal-title":"Contraception."},{"issue":"1A","key":"2021121111113407800_CIT0216","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0022-4731(89)90008-3","article-title":"Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration","volume":"32","author":"Heikinheimo","year":"1989","journal-title":"J Steroid Biochem."},{"issue":"5","key":"2021121111113407800_CIT0217","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0010-7824(86)90056-9","article-title":"Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women","volume":"34","author":"Swahn","year":"1986","journal-title":"Contraception."},{"issue":"1","key":"2021121111113407800_CIT0218","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/bmc.1086","article-title":"Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study","volume":"23","author":"Tang","year":"2009","journal-title":"Biomed Chromatogr."},{"issue":"10","key":"2021121111113407800_CIT0219","first-page":"1241","article-title":"Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects","volume":"46","author":"Teng","year":"2011","journal-title":"Yao Xue Xue Bao."},{"issue":"4","key":"2021121111113407800_CIT0220","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0022-4731(87)90160-9","article-title":"Pharmacokinetics and metabolism of RU 486","volume":"27","author":"L\u00e4hteenm\u00e4ki","year":"1987","journal-title":"J Steroid Biochem."},{"issue":"1","key":"2021121111113407800_CIT0221","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003088-199733010-00002","article-title":"Clinical pharmacokinetics of mifepristone","volume":"33","author":"Heikinheimo","year":"1997","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"2021121111113407800_CIT0222","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.contraception.2008.02.009","article-title":"Bioavailability of mifepristone in capsule versus tablet form in healthy nonpregnant women","volume":"77","author":"Liao","year":"2008","journal-title":"Contraception."},{"issue":"2","key":"2021121111113407800_CIT0223","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1208\/s12248-013-9559-2","article-title":"Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486)","volume":"16","author":"Wang","year":"2014","journal-title":"Aaps J."},{"issue":"2","key":"2021121111113407800_CIT0224","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.humrep.a136857","article-title":"Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose","volume":"4","author":"Cekan","year":"1989","journal-title":"Hum Reprod."},{"issue":"2","key":"2021121111113407800_CIT0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0010-7824(93)90004-Q","article-title":"Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women","volume":"48","author":"Shi","year":"1993","journal-title":"Contraception."},{"issue":"5","key":"2021121111113407800_CIT0226","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-2952(96)00357-7","article-title":"Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes","volume":"52","author":"Jang","year":"1996","journal-title":"Biochem Pharmacol."},{"issue":"1","key":"2021121111113407800_CIT0227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0009-2797(98)00115-X","article-title":"Mechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450","volume":"118","author":"Reilly","year":"1999","journal-title":"Chem Biol Interact."},{"issue":"9","key":"2021121111113407800_CIT0228","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1124\/dmd.30.9.985","article-title":"Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4","volume":"30","author":"Khan","year":"2002","journal-title":"Drug Metab Dispos."},{"issue":"5","key":"2021121111113407800_CIT0229","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0010-7824(93)90133-R","article-title":"Clinical pharmacology of RU 486\u2013an antiprogestin and antiglucocorticoid","volume":"48","author":"Spitz","year":"1993","journal-title":"Contraception."},{"issue":"6","key":"2021121111113407800_CIT0230","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Hum Reprod."},{"issue":"10","key":"2021121111113407800_CIT0231","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.steroids.2003.09.008","article-title":"Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy","volume":"68","author":"DeManno","year":"2003","journal-title":"Steroids."},{"issue":"5","key":"2021121111113407800_CIT0232","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/me.2006-0524","article-title":"A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator","volume":"21","author":"Madauss","year":"2007","journal-title":"Mol Endocrinol."},{"key":"2021121111113407800_CIT0233","first-page":"46","article-title":"Interspecies comparison: in vitro metabolism of J867 by hepatocytes and microsomes from male and female human, and various animal species","volume":"34","author":"Bilyeu","year":"2002","journal-title":"Drug Metab Rev"},{"issue":"10","key":"2021121111113407800_CIT0234","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0039-128X(00)00190-2","article-title":"Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium","volume":"65","author":"Chwalisz","year":"2000","journal-title":"Steroids."},{"issue":"10","key":"2021121111113407800_CIT0235","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0039-128X(03)00118-1","article-title":"Development of the selective progesterone receptor modulator CDB-2914 for clinical indications","volume":"68","author":"Blithe","year":"2003","journal-title":"Steroids."},{"issue":"5","key":"2021121111113407800_CIT0236","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/humrep\/15.5.1092","article-title":"A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women","volume":"15","author":"Stratton","year":"2000","journal-title":"Hum Reprod."},{"issue":"2","key":"2021121111113407800_CIT0237","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"issue":"6","key":"2021121111113407800_CIT0238","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate\u2606","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"issue":"9","key":"2021121111113407800_CIT0239","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/humrep\/del159","article-title":"Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells","volume":"21","author":"Xu","year":"2006","journal-title":"Hum Reprod."},{"issue":"3","key":"2021121111113407800_CIT0240","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0030-1251483","article-title":"Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth","volume":"28","author":"Yoshida","year":"2010","journal-title":"Semin Reprod Med."},{"issue":"4","key":"2021121111113407800_CIT0241","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/humrep\/15.4.822","article-title":"CDB-2914: anti-progestational\/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits","volume":"15","author":"Hild","year":"2000","journal-title":"Hum Reprod"},{"issue":"10","key":"2021121111113407800_CIT0242","first-page":"859","article-title":"Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids","volume":"8","author":"Orihuela","year":"2007","journal-title":"Curr Opin Investig Drugs."},{"issue":"5","key":"2021121111113407800_CIT0243","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/humrep\/15.5.1100","article-title":"Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration","volume":"15","author":"Larner","year":"2000","journal-title":"Hum Reprod."},{"issue":"4","key":"2021121111113407800_CIT0244","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jcpt.12065","article-title":"Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day","volume":"38","author":"Pohl","year":"2013","journal-title":"J Clin Pharm Ther."},{"issue":"1","key":"2021121111113407800_CIT0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5414\/CP201789","article-title":"Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole","volume":"51","author":"Pohl","year":"2013","journal-title":"Int J Clin Pharmacol Ther."},{"key":"2021121111113407800_CIT0246","first-page":"177","article-title":"Metabolic disposition of [14C] ulipristal acetate in healthy premenopausal women","volume":"5","author":"Pohl","year":"2013","journal-title":"J Bioequiv Availab"},{"issue":"4","key":"2021121111113407800_CIT0247","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1933719114549850","article-title":"The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids","volume":"22","author":"Pohl","year":"2015","journal-title":"Reprod Sci."},{"issue":"3","key":"2021121111113407800_CIT0248","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/modpathol.2008.204","article-title":"Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator","volume":"22","author":"Ioffe","year":"2009","journal-title":"Mod Pathol."},{"issue":"1","key":"2021121111113407800_CIT0249","first-page":"17","article-title":"Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding","volume":"3","author":"Wiehle","year":"2008","journal-title":"US Obstet Gynecol"},{"issue":"4","key":"2021121111113407800_CIT0250","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1208\/s12248-011-9304-7","article-title":"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance","volume":"13","author":"Morris","year":"2011","journal-title":"Aaps J."},{"issue":"3","key":"2021121111113407800_CIT0251","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/1940-6207.CAPR-10-0244","article-title":"CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis","volume":"4","author":"Wiehle","year":"2011","journal-title":"Cancer Prev Res (Phila)."},{"issue":"10","key":"2021121111113407800_CIT0252","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1210\/en.2018-00559","article-title":"Mechanism of telapristone acetate (CDB4124) on progesterone receptor action in breast cancer cells","volume":"159","author":"Davaadelger","year":"2018","journal-title":"Endocrinology."},{"issue":"1","key":"2021121111113407800_CIT0253","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-016-2355-5","article-title":"Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2\/M by repressing G2\/M genes","volume":"16","author":"Clare","year":"2016","journal-title":"BMC Cancer."},{"issue":"7","key":"2021121111113407800_CIT0254","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"2021121111113407800_CIT0255","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"2021121111113407800_CIT0256","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00280-015-2848-y","article-title":"Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation","volume":"76","author":"Lee","year":"2015","journal-title":"Cancer Chemother Pharmacol."},{"key":"2021121111113407800_CIT0257","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2017.02.002","article-title":"Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids","volume":"55","author":"Seitz","year":"2017","journal-title":"Contemp Clin Trials."},{"issue":"8","key":"2021121111113407800_CIT0258","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/humrep\/det247","article-title":"BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies","volume":"28","author":"Wagenfeld","year":"2013","journal-title":"Hum Reprod."},{"issue":"21","key":"2021121111113407800_CIT0259","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cmdc.201800487","article-title":"Discovery of vilaprisan (BAY 1002670): a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies","volume":"13","author":"M\u00f6ller","year":"2018","journal-title":"Chemmedchem."},{"issue":"1","key":"2021121111113407800_CIT0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5414\/CP202756","article-title":"Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women","volume":"55","author":"Schultze-Mosgau","year":"2017","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"8","key":"2021121111113407800_CIT0261","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40262-017-0607-4","article-title":"Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential","volume":"57","author":"Schultze-Mosgau","year":"2018","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"2021121111113407800_CIT0262","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol."},{"issue":"3","key":"2021121111113407800_CIT0263","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/1933719117746764","article-title":"Characterization of molecular changes in endometrium associated with chronic use of progesterone receptor modulators: ulipristal acetate versus mifepristone","volume":"25","author":"Kannan","year":"2018","journal-title":"Reprod Sci."},{"issue":"7","key":"2021121111113407800_CIT0264","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.humpath.2010.11.003","article-title":"Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone","volume":"42","author":"Fiscella","year":"2011","journal-title":"Hum Pathol."},{"issue":"6019","key":"2021121111113407800_CIT0265","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1126\/science.1197454","article-title":"The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2","volume":"331","author":"Li","year":"2011","journal-title":"Science."},{"issue":"11","key":"2021121111113407800_CIT0266","doi-asserted-by":"crossref","first-page":"e1001551","DOI":"10.1371\/journal.pmed.1001551","article-title":"Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development","volume":"10","author":"Jones","year":"2013","journal-title":"Plos Med."},{"issue":"4","key":"2021121111113407800_CIT0267","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.contraception.2018.05.020","article-title":"Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment","volume":"98","author":"Berger","year":"2018","journal-title":"Contraception."},{"issue":"10","key":"2021121111113407800_CIT0268","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1016\/j.bbagen.2013.05.011","article-title":"A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications","volume":"1830","author":"Nyren-Erickson","year":"2013","journal-title":"Biochim Biophys Acta."},{"issue":"2","key":"2021121111113407800_CIT0269","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.yexcr.2004.01.026","article-title":"Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity","volume":"295","author":"Barker","year":"2004","journal-title":"Exp Cell Res."},{"issue":"4","key":"2021121111113407800_CIT0270","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.1415","article-title":"Tenascins: regulation and putative functions during pathological stress","volume":"200","author":"Chiquet-Ehrismann","year":"2003","journal-title":"J Pathol"},{"issue":"6","key":"2021121111113407800_CIT0271","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa","year":"2010","journal-title":"Endocrinology."},{"issue":"12","key":"2021121111113407800_CIT0272","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/molehr\/8.12.1071","article-title":"Effects of GnRH analogues, \u2018add-back\u2019 steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression","volume":"8","author":"Chegini","year":"2002","journal-title":"Mol Hum Reprod."},{"issue":"3","key":"2021121111113407800_CIT0273","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7150\/ijms.7627","article-title":"Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro","volume":"11","author":"Chung","year":"2014","journal-title":"Int J Med Sci."},{"issue":"1","key":"2021121111113407800_CIT0274","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","article-title":"LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer","volume":"37","author":"Feng","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"issue":"12","key":"2021121111113407800_CIT0275","doi-asserted-by":"crossref","first-page":"e80114","DOI":"10.1371\/journal.pone.0080114","article-title":"GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment","volume":"8","author":"Engman","year":"2013","journal-title":"Plos One."},{"issue":"4","key":"2021121111113407800_CIT0276","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.fertnstert.2015.12.021","article-title":"Mifepristone inhibits extracellular matrix formation in uterine leiomyoma","volume":"105","author":"Patel","year":"2016","journal-title":"Fertil Steril."},{"issue":"6","key":"2021121111113407800_CIT0277","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0002-9378(94)70332-9","article-title":"The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study","volume":"170","author":"Reinsch","year":"1994","journal-title":"Am J Obstet Gynecol."},{"issue":"3","key":"2021121111113407800_CIT0278","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J Minim Invasive Gynecol."},{"issue":"5","key":"2021121111113407800_CIT0279","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstet Gynecol."},{"issue":"2","key":"2021121111113407800_CIT0280","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"2021121111113407800_CIT0281","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/IJWH.S33125","article-title":"Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial","volume":"5","author":"Carbonell","year":"2013","journal-title":"Int J Womens Health."},{"issue":"2","key":"2021121111113407800_CIT0282","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejogrb.2009.06.004","article-title":"Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata","volume":"146","author":"Eisinger","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"2","key":"2021121111113407800_CIT0283","first-page":"513","article-title":"Regression of uterine leiomyomata in response to the antiprogesterone RU 486","volume":"76","author":"Murphy","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121111113407800_CIT0284","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery","volume":"4","author":"Esteve","year":"2012","journal-title":"Int J Womens Health"},{"key":"2021121111113407800_CIT0285","doi-asserted-by":"crossref","first-page":"649030","DOI":"10.1155\/2013\/649030","article-title":"Treatment of uterine myoma with 2.5 or 5\u2009mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial","volume":"2013","author":"Carbonell","year":"2013","journal-title":"ISRN Obstet Gynecol."},{"issue":"2","key":"2021121111113407800_CIT0286","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol."},{"issue":"2","key":"2021121111113407800_CIT0287","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.fertnstert.2013.10.015","article-title":"Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study","volume":"101","author":"Yerushalmi","year":"2014","journal-title":"Fertil Steril."},{"issue":"4","key":"2021121111113407800_CIT0288","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2005-2379","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells","volume":"91","author":"Chen","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021121111113407800_CIT0289","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/humrep\/del035","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells","volume":"21","author":"Wang","year":"2006","journal-title":"Hum Reprod."},{"issue":"4","key":"2021121111113407800_CIT0290","doi-asserted-by":"crossref","first-page":"E1002","DOI":"10.1152\/ajpendo.00210.2007","article-title":"Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells","volume":"293","author":"Xu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"4","key":"2021121111113407800_CIT0291","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/humrep\/den025","article-title":"Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer","volume":"23","author":"Morikawa","year":"2008","journal-title":"Hum Reprod."},{"issue":"6","key":"2021121111113407800_CIT0292","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertil Steril."},{"issue":"12","key":"2021121111113407800_CIT0293","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021121111113407800_CIT0294","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/humrep\/dez007","article-title":"Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials","volume":"34","author":"Stewart","year":"2019","journal-title":"Hum Reprod."},{"issue":"2","key":"2021121111113407800_CIT0295","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/jc.2004-1569","article-title":"Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5\u2019-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells","volume":"90","author":"Xu","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021121111113407800_CIT0296","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1933719114542019","article-title":"Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells","volume":"21","author":"Ciarmela","year":"2014","journal-title":"Reprod Sci."},{"issue":"3","key":"2021121111113407800_CIT0297","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/molehr\/gan004","article-title":"Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells","volume":"14","author":"Xu","year":"2008","journal-title":"Mol Hum Reprod."},{"issue":"2","key":"2021121111113407800_CIT0298","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil Steril"},{"issue":"4","key":"2021121111113407800_CIT0299","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2017-02295","article-title":"Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment","volume":"103","author":"Courtoy","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121111113407800_CIT0300","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1933719117728802","article-title":"Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial","volume":"25","author":"Cox","year":"2018","journal-title":"Reprod Sci."},{"issue":"4","key":"2021121111113407800_CIT0301","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.fertnstert.2018.12.026","article-title":"Ulipristal acetate decreases active TGF-\u03b23 and its canonical signaling in uterine leiomyoma via two novel mechanisms","volume":"111","author":"Lewis","year":"2019","journal-title":"Fertil Steril"},{"issue":"3","key":"2021121111113407800_CIT0302","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.fertnstert.2017.11.023","article-title":"Ulipristal acetate decreases transforming growth factor \u03b23 serum and tumor tissue concentrations in patients with uterine fibroids","volume":"109","author":"Ciebiera","year":"2018","journal-title":"Fertil Steril"},{"issue":"2","key":"2021121111113407800_CIT0303","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.rbmo.2018.04.050","article-title":"Gene expression changes in uterine myomas in response to ulipristal acetate treatment","volume":"37","author":"Courtoy","year":"2018","journal-title":"Reprod Biomed Online."},{"issue":"4","key":"2021121111113407800_CIT0304","first-page":"970","article-title":"A-kinase anchoring protein 13 (AKAP13) augments progesterone signaling in uterine fibroid cells","volume":"104","author":"Ng","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2021121111113407800_CIT0305","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1933719118816836","article-title":"Ulipristal acetate mediates decreased proteoglycan expression through regulation of nuclear factor of activated T-Cells (NFAT5)","volume":"26","author":"Britten","year":"2019","journal-title":"Reprod Sci."},{"issue":"5","key":"2021121111113407800_CIT0306","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med."},{"key":"2021121111113407800_CIT0307","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","article-title":"Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results","volume":"208","author":"Fernandez","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"5","key":"2021121111113407800_CIT0308","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/AOG.0000000000002942","article-title":"Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Liu","year":"2018","journal-title":"Obstet Gynecol."},{"issue":"3","key":"2021121111113407800_CIT0309","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","article-title":"Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial","volume":"131","author":"Simon","year":"2018","journal-title":"Obstet Gynecol."},{"issue":"4","key":"2021121111113407800_CIT0310","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.fertnstert.2018.06.044","article-title":"Liver injury and ulipristal acetate: an overstated tragedy?","volume":"110","author":"Donnez","year":"2018","journal-title":"Fertil Steril."},{"issue":"5","key":"2021121111113407800_CIT0311","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet Gynecol."},{"issue":"9","key":"2021121111113407800_CIT0312","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121111113407800_CIT0313","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil Steril"},{"issue":"8","key":"2021121111113407800_CIT0314","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br J Obstet Gynaecol."},{"issue":"8","key":"2021121111113407800_CIT0315","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.fertnstert.2009.11.031","article-title":"The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells","volume":"93","author":"Luo","year":"2010","journal-title":"Fertil Steril."},{"issue":"9","key":"2021121111113407800_CIT0316","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/1933719111399929","article-title":"CDB-4124 does not cause apoptosis in cultured fibroid cells","volume":"18","author":"Roeder","year":"2011","journal-title":"Reprod Sci."},{"issue":"8","key":"2021121111113407800_CIT0317","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/humrep\/dew140","article-title":"Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women","volume":"31","author":"Sch\u00fctt","year":"2016","journal-title":"Hum Reprod."},{"issue":"2","key":"2021121111113407800_CIT0318","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jcph.998","article-title":"Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women","volume":"58","author":"Sch\u00fctt","year":"2018","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"2021121111113407800_CIT0319","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2018.10.012","article-title":"Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study","volume":"111","author":"Bradley","year":"2019","journal-title":"Fertil Steril."},{"issue":"5","key":"2021121111113407800_CIT0320","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0015-0282(00)01606-X","article-title":"RU486-induced growth inhibition of human endometrial cells","volume":"74","author":"Murphy","year":"2000","journal-title":"Fertil Steril."},{"issue":"5","key":"2021121111113407800_CIT0321","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0015-0282(02)03081-9","article-title":"Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro","volume":"77","author":"Jiang","year":"2002","journal-title":"Fertil Steril."},{"issue":"5","key":"2021121111113407800_CIT0322","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1210\/jc.2003-031945","article-title":"Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor","volume":"89","author":"Narvekar","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021121111113407800_CIT0323","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0015-0282(16)55705-7","article-title":"Time-related effects of RU486 treatment in experimentally induced endometriosis in the rat","volume":"59","author":"Tjaden","year":"1993","journal-title":"Fertil Steril."},{"issue":"3","key":"2021121111113407800_CIT0324","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0015-0282(16)54531-2","article-title":"Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis","volume":"56","author":"Kettel","year":"1991","journal-title":"Fertil Steril."},{"issue":"1","key":"2021121111113407800_CIT0325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(16)58022-4","article-title":"Treatment of endometriosis with the antiprogesterone mifepristone (RU486)","volume":"65","author":"Kettel","year":"1996","journal-title":"Fertil Steril."},{"issue":"1","key":"2021121111113407800_CIT0326","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jrhm.2015.09.001","article-title":"Mifepristone 2.5, 5, 10 mg versus placebo in the treatment of endometriosis","volume":"2","author":"Carbonell","year":"2016","journal-title":"J Reprod Health Med"},{"issue":"6","key":"2021121111113407800_CIT0327","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0002-9378(98)70316-3","article-title":"Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486)","volume":"178","author":"Kettel","year":"1998","journal-title":"Am J Obstet Gynecol."},{"key":"2021121111113407800_CIT0328","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.fertnstert.2004.07.212","article-title":"Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil","volume":"82","author":"Mattia-Goldberg","year":"2004","journal-title":"Fertil Steril"},{"issue":"2","key":"2021121111113407800_CIT0329","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejogrb.2013.03.022","article-title":"The effects of ulipristal on Bax\/Bcl-2, cytochrome c, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis","volume":"169","author":"Huniadi","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"1","key":"2021121111113407800_CIT0330","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12958-018-0347-9","article-title":"Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice","volume":"16","author":"Liang","year":"2018","journal-title":"Reprod Biol Endocrinol."},{"key":"2021121111113407800_CIT0331","article-title":"Treatment of endometriosis-related chronic pelvic pain with Ulipristal Acetate and associated endometrial changes","volume":"2","author":"Bressler","year":"2017","journal-title":"HSOA J Reprod Med Gynaecol Obstet."},{"issue":"7","key":"2021121111113407800_CIT0332","first-page":"CD009881","article-title":"Progesterone receptor modulators for endometriosis","volume":"7","author":"Fu","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021121111113407800_CIT0333","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.fertnstert.2005.01.126","article-title":"Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells","volume":"84","author":"Li","year":"2005","journal-title":"Fertil Steril."},{"issue":"6","key":"2021121111113407800_CIT0334","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/107155769800500611","article-title":"Inhibition of endometrial cancer cell lines by mifepristone (RU 486)","volume":"5","author":"Schneider","year":"1998","journal-title":"J Soc Gynecol Investig."},{"issue":"3","key":"2021121111113407800_CIT0335","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00280-007-0628-z","article-title":"In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines","volume":"62","author":"Navo","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"2021121111113407800_CIT0336","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jsbmb.2008.12.003","article-title":"Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa)","volume":"113","author":"\u00d8rbo","year":"2009","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"9","key":"2021121111113407800_CIT0337","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/cncr.24197","article-title":"Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma","volume":"115","author":"Ramondetta","year":"2009","journal-title":"Cancer."},{"issue":"3","key":"2021121111113407800_CIT0338","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2009.10.071","article-title":"A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study","volume":"116","author":"Rocereto","year":"2010","journal-title":"Gynecol Oncol."},{"issue":"15","key":"2021121111113407800_CIT0339","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-03-0637","article-title":"Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells","volume":"10","author":"Gaddy","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021121111113407800_CIT0340","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3892\/or.2013.2432","article-title":"RU486, a glucocorticoid receptor antagonist, induces apoptosis in U937 human lymphoma cells through reduction in mitochondrial membrane potential and activation of p38 MAPK","volume":"30","author":"Jang","year":"2013","journal-title":"Oncol Rep."},{"issue":"2","key":"2021121111113407800_CIT0341","first-page":"369","article-title":"Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1","volume":"23","author":"Liang","year":"2003","journal-title":"Int J Oncol."},{"issue":"3","key":"2021121111113407800_CIT0342","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1006\/bbrc.1993.2169","article-title":"Effects of the progestin antagonist RU 486 on T-47D breast cancer cell cycle kinetics and cell cycle regulatory genes","volume":"195","author":"Musgrove","year":"1993","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"2021121111113407800_CIT0343","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1210\/mend.11.1.9869","article-title":"Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21","volume":"11","author":"Musgrove","year":"1997","journal-title":"Mol Endocrinol."},{"issue":"1","key":"2021121111113407800_CIT0344","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canlet.2011.08.006","article-title":"The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1","volume":"312","author":"Benad","year":"2011","journal-title":"Cancer Lett."},{"issue":"1","key":"2021121111113407800_CIT0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.10665","article-title":"HDLG5\/KIAA0583, encoding a MAGUK-family protein, is a primary progesterone target gene in breast cancer cells","volume":"102","author":"Purmonen","year":"2002","journal-title":"Int J Cancer."},{"issue":"25","key":"2021121111113407800_CIT0346","doi-asserted-by":"crossref","first-page":"16791","DOI":"10.1074\/jbc.M808919200","article-title":"KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization","volume":"284","author":"Liu","year":"2009","journal-title":"J Biol Chem."},{"issue":"42","key":"2021121111113407800_CIT0347","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1038\/onc.2009.235","article-title":"Kr\u00fcppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1","volume":"28","author":"Zheng","year":"2009","journal-title":"Oncogene."},{"issue":"4","key":"2021121111113407800_CIT0348","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7150\/thno.14315","article-title":"Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression","volume":"6","author":"Liu","year":"2016","journal-title":"Theranostics."},{"issue":"11","key":"2021121111113407800_CIT0349","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/ijc.29304","article-title":"Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA\/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters","volume":"136","author":"Wargon","year":"2015","journal-title":"Int J Cancer."},{"issue":"4","key":"2021121111113407800_CIT0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ijc.1236","article-title":"Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells","volume":"92","author":"Hyder","year":"2001","journal-title":"Int J Cancer."},{"issue":"8","key":"2021121111113407800_CIT0351","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/en.2005-0103","article-title":"Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects","volume":"146","author":"Liang","year":"2005","journal-title":"Endocrinology."},{"issue":"20","key":"2021121111113407800_CIT0352","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1158\/0008-5472.CAN-07-1103","article-title":"Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics","volume":"67","author":"Liang","year":"2007","journal-title":"Cancer Res."},{"key":"2021121111113407800_CIT0353","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/srep07830","article-title":"Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex","volume":"5","author":"Yu","year":"2015","journal-title":"Sci Rep."},{"issue":"9","key":"2021121111113407800_CIT0354","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/humrep\/den228","article-title":"The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology","volume":"23","author":"Engman","year":"2008","journal-title":"Hum Reprod."},{"issue":"10","key":"2021121111113407800_CIT0355","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.1996.14.10.2709","article-title":"Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study","volume":"14","author":"Perrault","year":"1996","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021121111113407800_CIT0356","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12672-016-0255-4","article-title":"Anti-tumoral effects of anti-progestins in a patient-derived breast cancer xenograft model","volume":"7","author":"Esber","year":"2016","journal-title":"Horm Cancer."},{"issue":"1","key":"2021121111113407800_CIT0357","first-page":"167","article-title":"Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin","volume":"18","author":"Wiehle","year":"2007","journal-title":"Oncol Rep."},{"issue":"2","key":"2021121111113407800_CIT0358","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.canlet.2016.04.010","article-title":"Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation","volume":"376","author":"Lee","year":"2016","journal-title":"Cancer Lett."},{"key":"2021121111113407800_CIT0359","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jsbmb.2012.08.004","article-title":"Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells","volume":"133","author":"Gupta","year":"2013","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"6","key":"2021121111113407800_CIT0360","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol."},{"issue":"5","key":"2021121111113407800_CIT0361","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1679\/aohc.67.411","article-title":"Steroid receptors in blood vessels of the rhesus macaque endometrium: a review","volume":"67","author":"Brenner","year":"2004","journal-title":"Arch Histol Cytol."},{"issue":"5","key":"2021121111113407800_CIT0362","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.4049\/jimmunol.1300958","article-title":"Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil","volume":"191","author":"Wilkens","year":"2013","journal-title":"J Immunol."},{"issue":"2","key":"2021121111113407800_CIT0363","first-page":"232","article-title":"New concepts for an old problem: the diagnosis of endometrial hyperplasia","volume":"23","author":"Sanderson","year":"2017","journal-title":"Hum Reprod Update."},{"issue":"1","key":"2021121111113407800_CIT0364","doi-asserted-by":"crossref","first-page":"e8.","DOI":"10.3802\/jgo.2016.27.e8","article-title":"Therapeutic options for management of endometrial hyperplasia","volume":"27","author":"Chandra","year":"2015","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"2021121111113407800_CIT0365","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jogoh.2019.03.015","article-title":"Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant","volume":"48","author":"P\u00e9cout","year":"2019","journal-title":"J Gynecol Obstet Hum Reprod."},{"key":"2021121111113407800_CIT0366","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jogc.2018.05.020","article-title":"Pregnancy outcomes following ulipristal acetate for uterine fibroids: a systematic review","volume":"40","author":"De Gasperis-Brigante","year":"2018","journal-title":"J Obstet Gynaecol Can"},{"issue":"5","key":"2021121111113407800_CIT0367","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1471-0528.12147","article-title":"Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study","volume":"120","author":"Bernard","year":"2013","journal-title":"Bjog."},{"issue":"4","key":"2021121111113407800_CIT0368","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1056\/NEJM197607222950406","article-title":"Current concepts in genetics. Congenital malformations","volume":"295","author":"Sutcliffe","year":"1976","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121111113407800_CIT0369","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.contraception.2014.01.003","article-title":"Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women","volume":"89","author":"Levy","year":"2014","journal-title":"Contraception."},{"key":"2021121111113407800_CIT0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.contraception.2017.10.003","article-title":"Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014","volume":"97","author":"Kavanaugh","year":"2018","journal-title":"Contraception"},{"key":"2021121111113407800_CIT0371","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40834-018-0067-8","article-title":"State of emergency contraception in the U.S., 2018","volume":"3","author":"Haeger","year":"2018","journal-title":"Contracept Reprod Med."},{"issue":"15","key":"2021121111113407800_CIT0372","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199210083271501","article-title":"Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception","volume":"327","author":"Glasier","year":"1992","journal-title":"N Engl J Med."},{"issue":"6","key":"2021121111113407800_CIT0373","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/jcem-65-6-1135","article-title":"Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486","volume":"65","author":"Liu","year":"1987","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121111113407800_CIT0374","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0010-7824(03)00146-X","article-title":"A single dose of mifepristone (200 mg) in the immediate preovulatory phase offers contraceptive potential without cycle disruption","volume":"68","author":"Brown","year":"2003","journal-title":"Contraception."},{"issue":"2","key":"2021121111113407800_CIT0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.contraception.2016.03.009","article-title":"Effects of low doses of mifepristone on human embryo implantation process in a three-dimensional human endometrial in vitro co-culture system","volume":"94","author":"Boggavarapu","year":"2016","journal-title":"Contraception."},{"issue":"3","key":"2021121111113407800_CIT0376","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.fertnstert.2011.06.074","article-title":"Low-dose mifepristone increases uterine natural killer cell cytotoxicity and perforin expression during the receptive phase","volume":"96","author":"Zhou","year":"2011","journal-title":"Fertil Steril."},{"issue":"4","key":"2021121111113407800_CIT0377","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0010-7824(02)00513-9","article-title":"Progesterone receptor isoform B in the human fallopian tube and endometrium following mifepristone","volume":"67","author":"Sun","year":"2003","journal-title":"Contraception."},{"issue":"2","key":"2021121111113407800_CIT0378","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1073\/pnas.91.2.529","article-title":"Progesterone and RU486: opposing effects on human sperm","volume":"91","author":"Yang","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2021121111113407800_CIT0379","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2605.1996.tb00436.x","article-title":"RU486 inhibits penetration of human spermatozoa into zona-free hamster oocytes","volume":"19","author":"Yang","year":"1996","journal-title":"Int J Androl."},{"issue":"5","key":"2021121111113407800_CIT0380","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3109\/00016341003721037","article-title":"Medical abortion in lactating women\u2013low levels of mifepristone in breast milk","volume":"89","author":"S\u00e4\u00e4v","year":"2010","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"6","key":"2021121111113407800_CIT0381","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.AOG.0000146286.60138.47","article-title":"A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception","volume":"104","author":"Hamoda","year":"2004","journal-title":"Obstet Gynecol."},{"issue":"6","key":"2021121111113407800_CIT0382","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1479-828X.2005.00483.x","article-title":"Comparison of three single doses of mifepristone as emergency contraception: a randomised controlled trial","volume":"45","author":"Jin","year":"2005","journal-title":"Aust N Z J Obstet Gynaecol."},{"issue":"2","key":"2021121111113407800_CIT0383","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/13625180701330480","article-title":"Emergency contraception in Cuba with 10 mg of mifepristone","volume":"12","author":"Carbonell Esteve","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"2021121111113407800_CIT0384","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/AOG.0b013e3181d43ae4","article-title":"Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial","volume":"115","author":"Wu","year":"2010","journal-title":"Obstet Gynecol."},{"issue":"9","key":"2021121111113407800_CIT0385","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/humrep\/deq157","article-title":"Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture","volume":"25","author":"Brache","year":"2010","journal-title":"Hum Reprod."},{"issue":"3","key":"2021121111113407800_CIT0386","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-0036-1572438","article-title":"Emergency contraception: two steps forward, one step back","volume":"34","author":"Davis","year":"2016","journal-title":"Semin Reprod Med."},{"issue":"5","key":"2021121111113407800_CIT0387","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.contraception.2013.05.010","article-title":"Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens","volume":"88","author":"Brache","year":"2013","journal-title":"Contraception."},{"key":"2021121111113407800_CIT0388","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mce.2018.04.010","article-title":"A single preovulatory administration of ulipristal acetate affects the decidualization process of the human endometrium during the receptive period of the menstrual cycle","volume":"476","author":"Lira-Albarr\u00e1n","year":"2018","journal-title":"Mol Cell Endocrinol."},{"issue":"6","key":"2021121111113407800_CIT0389","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.fertnstert.2008.12.057","article-title":"Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914","volume":"93","author":"Stratton","year":"2010","journal-title":"Fertil Steril."},{"issue":"6","key":"2021121111113407800_CIT0390","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.contraception.2017.02.019","article-title":"Study of the effect of ulipristal acetate on human sperm ability to interact with tubal tissue and cumulus-oocyte-complexes","volume":"95","author":"Zumoffen","year":"2017","journal-title":"Contraception."},{"issue":"6","key":"2021121111113407800_CIT0391","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/13625187.2012.725877","article-title":"Effect of exposure to ulipristal acetate on sperm function","volume":"17","author":"Munuce","year":"2012","journal-title":"Eur J Contracept Reprod Health Care."},{"issue":"4","key":"2021121111113407800_CIT0392","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/humrep\/dev030","article-title":"Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system","volume":"30","author":"Berger","year":"2015","journal-title":"Hum Reprod."},{"issue":"10","key":"2021121111113407800_CIT0393","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/humrep\/deu210","article-title":"Ulipristal acetate resembles mifepristone in modulating human fallopian tube function","volume":"29","author":"Li","year":"2014","journal-title":"Hum Reprod."},{"key":"2021121111113407800_CIT0394","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/humrep\/dew055","article-title":"Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation","volume":"31","author":"Li","year":"2016","journal-title":"Hum Reprod"},{"issue":"5","key":"2021121111113407800_CIT0395","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.AOG.0000239440.02284.45","article-title":"Progesterone receptor modulator for emergency contraception: a randomized controlled trial","volume":"108","author":"Creinin","year":"2006","journal-title":"Obstet Gynecol."},{"issue":"9714","key":"2021121111113407800_CIT0396","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(10)60101-8","article-title":"Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis","volume":"375","author":"Glasier","year":"2010","journal-title":"Lancet."},{"issue":"2 Pt 1","key":"2021121111113407800_CIT0397","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/AOG.0b013e3181c8e2aa","article-title":"Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception","volume":"115","author":"Fine","year":"2010","journal-title":"Obstet Gynecol."},{"issue":"4","key":"2021121111113407800_CIT0398","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of cushing\u2019s disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev."},{"issue":"7","key":"2021121111113407800_CIT0399","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021121111113407800_CIT0400","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021121111113407800_CIT0401","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metab."},{"issue":"4","key":"2021121111113407800_CIT0402","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MED.0b013e32835430bf","article-title":"The use of the glucocorticoid receptor antagonist mifepristone in Cushing\u2019s syndrome","volume":"19","author":"Castinetti","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"3","key":"2021121111113407800_CIT0403","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/phar.1202","article-title":"Mifepristone for management of Cushing\u2019s syndrome","volume":"33","author":"Morgan","year":"2013","journal-title":"Pharmacotherapy."},{"issue":"8","key":"2021121111113407800_CIT0404","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021121111113407800_CIT0405","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing\u2019s syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2021121111113407800_CIT0406","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021121111113407800_CIT0407","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/cen.12332","article-title":"Global clinical response in Cushing\u2019s syndrome patients treated with mifepristone","volume":"80","author":"Katznelson","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"12","key":"2021121111113407800_CIT0408","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1210\/jc.2018-02638","article-title":"Mifepristone treatment in four cases of primary bilateral macronodular adrenal hyperplasia (BMAH)","volume":"104","author":"Cohan","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021121111113407800_CIT0409","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121111113407800_CIT0410","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","article-title":"Sustained weight loss in patients treated with mifepristone for Cushing\u2019s syndrome: a follow-up analysis of the SEISMIC study and long-term extension","volume":"15","author":"Fein","year":"2015","journal-title":"BMC Endocr Disord."},{"issue":"11","key":"2021121111113407800_CIT0411","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1176\/appi.ajp.159.11.1855","article-title":"Prevalence of depressive episodes with psychotic features in the general population","volume":"159","author":"Ohayon","year":"2002","journal-title":"Am J Psychiatry."},{"issue":"3","key":"2021121111113407800_CIT0412","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.biopsych.2005.10.014","article-title":"Cortisol circadian rhythm alterations in psychotic major depression","volume":"60","author":"Keller","year":"2006","journal-title":"Biol Psychiatry."},{"issue":"4","key":"2021121111113407800_CIT0413","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/JCP.0b013e3182239191","article-title":"Efficacy and safety of mifepristone for the treatment of psychotic depression","volume":"31","author":"Blasey","year":"2011","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"2021121111113407800_CIT0414","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JCP.0000000000000744","article-title":"Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression","volume":"37","author":"Block","year":"2017","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"2021121111113407800_CIT0415","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopsych.2018.01.008","article-title":"Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response","volume":"84","author":"Block","year":"2018","journal-title":"Biol Psychiatry."},{"issue":"12","key":"2021121111113407800_CIT0416","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.biopsych.2006.05.034","article-title":"Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression","volume":"60","author":"DeBattista","year":"2006","journal-title":"Biol Psychiatry."}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnaa012\/33184195\/bnaa012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/41\/5\/bnaa012\/41724102\/edrv_41_5_bnaa012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/41\/5\/bnaa012\/41724102\/edrv_41_5_bnaa012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T21:28:03Z","timestamp":1666474083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/doi\/10.1210\/endrev\/bnaa012\/5828992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":416,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,4]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnaa012","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,5,4]]},"article-number":"bnaa012"}}